Alvotech (ALVO)
NASDAQ:ALVO
Want to see ALVO full AI Analyst Report?
ALVO Stock Chart & Stats
$3.61
$0.06(0.46%)
At close: 4:00 PM EST
$3.61
$0.06(0.46%)
Day’s Range― - ―
52-Week Range$3.03 - $11.85
Previous CloseN/A
Volume41.59K
Average Volume (3M)400.64K
Market Cap
$1.04B
Enterprise Value$2.44B
Total Cash (Recent Filing)$63.83M
Total Debt (Recent Filing)$1.46B
Price to Earnings (P/E)275.0
Beta1.02
Next Earnings
Aug 19, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.29
Shares Outstanding312,048,280
10 Day Avg. Volume447,145
30 Day Avg. Volume400,644
Financial Highlights & Ratios
PEG Ratio-0.46
Price to Book (P/B)-5.03
Price to Sales (P/S)2.44
P/FCF Ratio-12.49
Enterprise Value/Market Cap2.34
Enterprise Value/Revenue4.35
Enterprise Value/Gross Profit7.10
Enterprise Value/Ebitda-62.24
Forecast
1Y Price Target
$4.67Price Target Upside29.27% Upside
Rating ConsensusHold
Number of Analyst Covering3
EPS Forecast (FY)0.06
Revenue Forecast (FY)$616.56M
Bulls Say, Bears Say
Bulls Say
Scaled Revenue & Strong Gross MarginsAlvotech scaled revenues materially (from ~$37M in 2021 to ~$586M in 2025) while maintaining ~60% gross margins. A large top‑line base and stable unit economics indicate durable manufacturing efficiency and pricing leverage that support sustained profitability as volumes grow.
Commercial Momentum & Broad Market ReachMarket share gains (AVT02 fastest‑growing Humira biosimilar ~10% US share), five on‑market biosimilars and distribution across ~90 countries show proven commercialization and partner execution. This durable commercial footprint lowers go‑to‑market risk and supports recurring, diversified revenue streams.
Manufacturing Diversification With FujifilmThe Fujifilm manufacturing partnership adds U.S. capacity and a second supply source, reducing dependence on a single facility. Structural diversification improves supply resilience, mitigates regulatory single‑site risk, and enables faster, more reliable U.S. product launches as commercial volumes expand.
Bears Say
High Leverage & Negative EquityThe capital structure is heavily leveraged with total debt roughly exceeding assets and persistent negative equity. High leverage constrains strategic flexibility, increases refinancing and covenant risk, and amplifies sensitivity to interest rate moves, limiting long‑term optionality.
Persistent Cash Burn & Limited LiquidityOperating and free cash flows are persistently negative and cash on hand was modest at quarter end. Continued cash burn requires external financing or milestone receipts, raising refinancing and dilution risk and constraining the firm's ability to fund launches, capex or R&D without recurring financing.
Regulatory Overhang And Suppressed Product MarginsInspection‑driven slowdowns and prior FDA observations have depressed product throughput and margins (product margin ~11%). Ongoing remediation and BLA resubmission timing create structural execution risk that can delay commercial ramps, keep margins suppressed, and extend revenue volatility.
Alvotech News
ALVO FAQ
What was Alvotech’s price range in the past 12 months?
Alvotech lowest stock price was $3.03 and its highest was $11.85 in the past 12 months.
What is Alvotech’s market cap?
Alvotech’s market cap is $1.04B.
When is Alvotech’s upcoming earnings report date?
Alvotech’s upcoming earnings report date is Aug 19, 2026 which is in 87 days.
How were Alvotech’s earnings last quarter?
Alvotech released its earnings results on May 06, 2026. The company reported -$0.09 earnings per share for the quarter, missing the consensus estimate of -$0.047 by -$0.043.
Is Alvotech overvalued?
According to Wall Street analysts Alvotech’s price is currently Undervalued.
Does Alvotech pay dividends?
Alvotech does not currently pay dividends.
What is Alvotech’s EPS estimate?
Alvotech’s EPS estimate is -0.02.
How many shares outstanding does Alvotech have?
Alvotech has 312,048,280 shares outstanding.
What happened to Alvotech’s price movement after its last earnings report?
Alvotech reported an EPS of -$0.09 in its last earnings report, missing expectations of -$0.047. Following the earnings report the stock price went down -10.364%.
Which hedge fund is a major shareholder of Alvotech?
Currently, no hedge funds are holding shares in ALVO
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Alvotech Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$4.67 (29.27% Upside)
$4.67 (29.27% Upside)
Blogger Sentiment
Bullish
ALVO Sentiment 70%
Sector Average ―
Sector Average ―
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 3.8%
Last 30 Days ▼ 3.8%
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-66.39%
12-Months-Change
Fundamentals
Return on Equity
35.22%
Trailing 12-Months
Asset Growth
14.11%
Trailing 12-Months
Company Description
Alvotech
Alvotech, through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide. It offers biosimilar products in the therapeutic areas of autoimmune, eye, and bone disorders, as well as cancer. The company's lead program is AVT02, a high concentration formulation biosimilar to Humira to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT04, a biosimilar to Stelara to treat various inflammatory conditions comprising psoriatic arthritis, Crohn's disease, ulcerative colitis, plaque psoriasis, and other indications; AVT06, a biosimilar to Eylea to treat various conditions, such as age-related macular degeneration, macular edema, and diabetic retinopathy; and AVT03, a biosimilar to Xgeva and Prolia, which is in the pre-clinical phase to treat prevent bone fracture, spinal cord compression, and the need for radiation or bone surgery in patients with certain types of cancer, as well as prevent bone loss and increase bone mass. It also offers AVT05, a biosimilar to Simponi and Simponi Aria, which is in early phase development to treat various inflammatory conditions, including rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, and other indications; AVT16, a biosimilar to an immunology product; AVT23, a biosimilar to Xolair, which is in late-stage development to treat nasal polyps; and AVT33, a biosimilar to an oncology product. The company was founded in 2013 and is headquartered in Reykjavik, Iceland.
ALVO Company Deck
ALVO Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a balanced picture: strong pipeline momentum, rising EBITDA margins, meaningful commercial traction (notably AVT02 market share), a strategic Fujifilm manufacturing partnership and constructive full-year guidance are clear positives. Offsetting these are a material Q1 revenue decline (-20% YoY) and low product margin (11%) driven by deliberate manufacturing slowdowns to address regulatory findings, along with negative operating cash flow, a modest cash balance ($64M) and substantial quarterly interest payments. The company emphasizes derisking for stronger 2027 growth, but near-term financial and regulatory execution risks remain.View all ALVO earnings summariesALVO Stock 12 Month Forecast
Average Price Target
$4.67
▲(29.27% Upside)
Technical Analysis
Perrigo Company
―
Supernus Pharmaceuticals
―
ANI Pharmaceuticals
―
HUTCHMED
―
Amneal Pharmaceuticals
―
Ownership Overview
―
Insiders
1.54% Mutual Funds
1.59% Other Institutional Investors
96.32% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---